Emmes, a global, full-service clinical research organization (CRO), acquired VaxTRIALS. Based in Panama City, Panama, VaxTRIALS’ 160-plus staff members manage and monitor vaccine clinical trial activities throughout Latin America.

VaxTRIALS’ vaccine-related clinical trials have been conducted in 11 Latin American countries, as well as the Philippines.

VaxTRIALS’ staff members have supported clinical trials aimed at preventing diseases such as influenza, dengue, chikungunya, hepatitis A, meningitis, norovirus, herpes zoster, pertussis, respiratory syncytial virus (RSV), polio and COVID-19.
 
“VaxTRIALS is a highly complementary match for Emmes,” said Emmes CEO Peter Ronco. “It extends our global reach from our current base in North America, Europe, and Asia to Latin America, one of the fastest-growing regions for clinical trials due to its large, diverse patient population and high-quality clinical research sites. VaxTRIALS adds a number of new biopharmaceutical and public-private partnership clients and further strengthens one of our largest research therapeutic areas: vaccines and infectious diseases.”

“Both our companies have built enduring customer relationships and a legacy of service in vaccine and infectious disease research,” said VaxTRIALS CEO José Jimeno. “I am proud that we have made both people and cultural development a priority, including hiring and developing employees who care deeply about making a difference in public health.”